chronic hepatits B
Conditions
Interventions
Case series:Nil
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 or above (including 18 years old when signing the informed consent) male and female; 2. Patients who were HBeAg positive at the beginning of oral antiviral therapy; 3. Patients who met the drug withdrawal criteria in the guidelines for the prevention and treatment of chronic hepatitis B (2015) in China; 4. Patients who can participate in regular follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated with interferon antiviral therapy. 2. Patients who have been treated with immunomodulators such as thymosin and glucocorticoid. 3. Patients with compensated cirrhosis, that means met at least 2 of the following 4 criteria: (1) Ultrasound, CT and other imaging examinations suggested one of the changes in liver cirrhosis: irregular liver surface, granule or nodular liver parenchyma, with or without splenomegaly (splenic thickness > 4.0cm or greater than 5 rib units); (2) Routine blood PLT 1.3 or longer than PT 3s (discontinued thrombolysis or anticoagulant for more than 7 days); (4) Determination of liver elasticity >12.4kPa (ALT100ng/ml and imaging indicated the possibility of malignant liver occupying, or AFP>100ng/ml for 3 months; 6. Patients with HCV or HIV infection were excluded. Patients who were combined with alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease, drug-induced liver disease, severe fatty liver disease and other chronic liver diseases were excluded; 7. Patients with other malignancies requiring chemotherapy or other diseases requiring immunomodulatory therapy; 8. Patients who are not fit for this study judged by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV RNA;HBV DNA;HBsAg/HBsAb;HBeAg/HBeAb;Liver function test; | — |
Countries
China
Contacts
Public ContactLai Wei
Peking University People's Hospital
Outcome results
None listed